Sort by
Keyphrases
5-year Survival
28%
Chemotherapy
14%
Chemotherapy Regimen
14%
Cisplatin
28%
Cisplatin-based Chemotherapy
14%
Combination Strategy
14%
Concurrent Chemoradiation
100%
Confidence Interval
42%
Follow-up Time
14%
Kaplan-Meier Analysis
14%
Long-term Survival
14%
Non-small Cell Lung Cancer (NSCLC)
100%
Nonhematologic
14%
Once-daily
28%
Optimal Combination
14%
Overall Survival
14%
Performance Status
14%
Phase II Trial
14%
Radiotherapy Alone
14%
Randomized Phase III Trial
100%
Sequential Chemotherapy
14%
Sequential Delivery
14%
Sequential Therapy
14%
Sequential Treatment
14%
Stage III Non-small Cell Lung Cancer
14%
Statistical Test
14%
Survival Benefit
28%
Survival Effect
14%
Survival Time
14%
Thoracic Radiotherapy
100%
Time to Tumor Progression
14%
Toxic Effects
42%
Tumor Response
14%
Twice Daily
28%
Vinblastine
14%
Wilcoxon Rank Sum Test
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Chemotherapy
100%
Cisplatin
75%
Etoposide
25%
Long Term Survival
25%
Neoplasm
25%
Non Small Cell Lung Cancer
100%
Overall Survival
25%
Survival Time
25%
Toxicity
75%
Tumor Growth
25%
Vinblastine
25%
Medicine and Dentistry
Arm
100%
Chemoradiotherapy
100%
Chemotherapy
11%
Cisplatin
33%
Etoposide
11%
Kaplan Meier Method
11%
Long Term Survival
11%
Neoplasm
11%
Non Small Cell Lung Cancer
100%
Overall Survival
11%
Radiation Therapy
77%
Rank Sum Test
11%
Survival Time
11%
Toxicity
33%
Tumor Progression
11%
Vinblastine
11%
Nursing and Health Professions
Chemoradiotherapy
100%
Cisplatin
42%
Confidence Interval
42%
Etoposide
14%
Kaplan Meier Method
14%
Long Term Survival
14%
Neoplasm
14%
Non Small Cell Lung Cancer
100%
Overall Survival
14%
Radiotherapy
100%
Rank Sum Test
14%
Survival Time
14%
Toxicity
42%
Tumor Growth
14%
Agricultural and Biological Sciences
Confidence Interval
100%
Endpoints
66%
Lung
100%